coronary angioplastycoronary stentsrestenosisprophylaxismedicinal stentsrapamycinmaxolкоронарная ангиопластикакоронарные стентырестенозпрофилактикавыделяющие лекарства стентырапамицинтаксол1.Topol E. J., Serruys P. W. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-1820.2.Fischman D. L., Leon M. В., Bain D. S. et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 1994; 331: 496-501.3.Serruys P. W., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Ibid. 489-495.4.Sigwart U., Pael J., Mirkovitch V. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. Ibid. 1987; 316: 701-706.5.Topol E. J. Coronary-artery stents-gauging, gorging, and gouging. Ibid. 1998; 339: 1702-1704.6.Serruys P. W., Foley D. P., Suttorp M.-J. et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. J. Am. Coll. Cardiol. 2002; 39: 393-399.7.Va den Brand M., Reusing J., Morel M. M. et al. The effect of completeness of revascularization on event-free survival at one-year in the ARTS trial. Ibid. 559-564.8.El-Omar M. M., Dangas G., lakovou I. et al. Update on instent restenosis. Curr. Interv. Cardiol. Rep. 2001; 3: 296-305.9.Teirstein P. S., Massullo V., Jani S. et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N. Engl. J. Med. 1997; 336: 1697-1703.10.Malhotra S., Teirstein P. S. The SCRIPPS trial. Catheter-based radiotherapy to inhibit coronary restenosis. J. Invasive Cardiol. 2000; 12 (6): 330-332.11.Leon M. В., Teirstein P. S., Moses J. W. et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N. Engl. J. Med. 2001; 344 (4): 250-256.12.Teirstein P. S., Kuntz R. E. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation 2001; 104 (21): 2620-2626.13.Wilentz J. R., Sanborn T. A., Haudenschild С. С. et al. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987; 76 (3): 636-642.14.Wilensky R. I., March K. L., Gradus-Pizlo I. et al. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Ibid. 1995; 92 (10): 2995-3005.15.Stoltenberg R. L., Geraghty J., Steele D. M. et al. Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Transplantation. 1995; 60 (9): 993-998.16.Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994; 89: 2888-2891.17.Schwartz R., Holmes D., Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 1993; 20: 1284-1293.18.Schwartz R. S., Murphy J. G., Edwards W. D. et al. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990; 82: 2190-2200.19.Ross R., Wight T. N.. Strandness E. et al. Human atherosclerosis.I. Cell constitution and characteristics of advanced lesions of the superficial femoral arthery. Am. J. Pathol. 1984; 114: 79-93.20.Moses P. R. L., Campbell G. R., Wang Z. L. et al. Smooth muscle phenotypic expression in human carotid arteries. Lab. Invest. 1985; 53: 556-562.21.Austin G. E., Retliff N. В., Hollman J. et al. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 1985; 6: 369-375.22.Clowes A. W., Reidy M. A., Clowes M. M. Kinetics of cellular proliferation after arterial injury. Lab. Invest. 1983; 49: 327-333.23.Schwartz S. M., deBlois D., O'Brien E. R. M. The intima: soil for atherosclerosis and restenosis. Circ. Res. 1995; 77: 445-465.24.Morishita R., Gibbons G. H., Ellison К. Е., el al. Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 1993; 90: 8474-8478.25.Sirois M. G., Simons M., Edelman B. R. et al. Platelet release of platelet derived growth factor is required for intimal hyperplasia in rate vascular injury model. Circulation 1994; 90 (suppi. 1): 1-511.26.Mintz G. S., Popma J. J., Hong M. K. et al. Intravascular ultrasound to discern devicaspecific effects and mechanisms of restenosis. Am. J. Cardiol. 1996; 78: 18-22.27.Edelman E. R., Rogers С. Pathobiologic responses to stenting. Ibid. 1998; 81: 4E-6E.28.Komatsu R., Ueda M., Naruko T. et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.29.Kornowski R., Hong M. K., Tio F. O. et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 1998; 31: 224- 230.30.Jawien A., Bowen-Pope D. F., Lindner V. et al. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 1992; 89: 507-511.31.Sriram V., Patterson С. Cell cycle in vasculoproliferative diseases-potential Interventions and routes of delivery. Circulation 2001; 103: 2414-2419.32.Koster R., Vieluf D., Kiehn M. et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356: 1895-1897.33.Crook M. F., Newby A. C., Southgate К. М. Expression of intercellular adhesion molecules in human saphenous veins: effects of inflammatory of cytokines and neointimal formation in culture. Atherosclerosis. 2000; 50 (1): 33-41.34.Galto R., Padurean A., Jayaraman T. et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-2170.35.Suzuki Т., Kopia G., Shin-ichiro H. et al. Stent-based delivery of sirolimus reduces Neointimal formation in a porcine coronary model. Ibid. 2001; 104: 1188-1193.36.Heldman A. W., Cheng L., Jenkins G. M. et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Ibid. 103 (18): 2289-2295.37.Marx S. O., Marks A. R. Bench to bedside: The development of rapamycin and its application to stent restenosis. Ibid. 104: 852-855.38.Kipshidze N., Moses J. W., Leon M. B. Paclitaxel-coated stentis there a light at the end of the tunnel? J. Am. Coll. Cardiol. 2001; 38 (1): 292-293.39.Herdeg C., Oderhoff M., Baumbach A. et al. Local Paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. Ibid. 2000; 35 (7): 1996-1976.40.Schink J. С. Etoposide, methotrexate, actinomycin cyclophosphamide, and vincristine for the treatment of meta risk gestational trophoblastic disease. Obstet. and Gynecol. 1992; 80 (5): 817-820.41.Bailey S. Local drug delivery during percutaneous coronary intervention. Curr. Interv. Cardiol. Rep. 2000; 2 (4): 349-357.42.Kipshidze N., Moses J., Shankar L. R. et al. Perspectives on antisense therapy for the prevention of restenosis. Curr. Opin. Mol. Ther. 2001; 3 (3): 265-277.43.Oberhoff M., Herdeg C., Ghobainy R. et al. Local delivery of Paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Cathet. Cardiovasc. Inverv. 2001; 53 (4): 562-568.44.Etienson D. S., Edelman E. R. Local drug delivery: an emerging approach in the treatment of restenosis. Vase. Med. 2000; 5 (2): 97-102.45.Hofma S. H., van Beusekom H. M., Serruys P. W. et al. Recent developments in coated stents. Curr. Inverv. Cardiol. Rep. 2001; 3 (1): 28-36.46.Xiaoshun L., Huang Y., De Scheerder I. Study of antirestenosis with the Biodivysio dexamethasone eluting stent (STRIDE): a multicenter trial. J. Am. Coll. Cardiol., 2002; 39 (5, suppl. A, 15A): 1052, abstr. 7.47.Sousa J. E., Costa M. A., Abizaid A. et al. Lack of neointimal proliferation after implantation of Sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular study. Circulation 2001; 103 (92): 192-195.48.Sousa J., Costa M. A., Abizaid A. C. et al. Sustained suppression of neointimal proliferation by Sirolimus-eluting stents. Ibid. 104: 2007.49.Morice M. C., Serruys P. W., Sousa J. E. et al. A randomized comparison of a Sirolimus eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 2002; 346 (23): 1773-1780.50.Abizaid A., Serruys P., Abizaid A. et al. The absence of edge effect after implantation of Sirolimus-eluting stents to treat instent restenosis: a three-dimensional intravascular ultrasound volumetric analysis [abstract]. J. Am. Coll. Cardiol. 2002; 39 (5, suppl. A, 58A): 1174, abstr. 14.51.Muzaffer D., Tanabe E., Regar J. et al. Are sirolimus-eluting stents inducing vascular remodeling? A subgroup analysis of 3D-intravascular ultrasound in the RAVEL trial. Ibid. (5, suppl. A, 59A): 1174, abstr. 18.52.Moses J. W., Leon M. В., Popma J. J. et al. The U. S. multicenter, randomized, double-blind study of the Sirolimus-eluting stent in coronary lesions: Early (30-day) safety results. Circulation 2001; 104 (17, suppl. II): abstr. 2200.53.Park S. J., Won H. S., Ho D. S. et al. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial. Ibid, abstr. 2199.54.Chevalier В., De Scheerder I., Gershlick A. et al. Effect on restenosis with a paclitaxel eluting stent: factors associated with inhibition in the Elutes clinical study. J. Am. Coll. Cardiol., 2002; 39 (5, suppl. A, 59A): 1174.55.Grube E., Silber S. M., Hauptmann K. E. et al. Taxus 1: prospective, randomized, double-blind comparison of NIRx™ stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. Circula- tion 2001; 104 (17, suppl. II): abstr. 2197.56.Grube E., Serruys P. W. Safety and performance of a paclitaxel-eluting stent for the treatment of in-stent restenosis: preliminary results of the Taxus III trial. J. Am. Coll. Cardiol., 2002; 39 (5, suppl. A, 58A): 1174. abstr. 15.57.Chao-Wei H., Wu D., Edelman E. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001; 104: 600-605.58.De Scheerder I., Yanming H., Dens J. et al. Treatment of instent restenosis using paclitaxel eiuting stents: A single centre pilot trial. Ibid. Suppl. II: abstr. 3503.59.LiistroI., Colombo A. Late acute thrombosis after paclitaxel eiuting stent implantation. Heart 2001: 86 (3): 262-264.60.Degertekin M., Regar E., Tanabe K. et al. Incidence of incomplete stent apposition at six-month follow-up in the multi center RAVEL trial. J. Am. Coll. Cardiol. 2002; 39 (5, suppl. A, 38A): 823-825.61.Serruys P., Abizaid A., Foley D. et al. Sirolimus-eluting stents abolish neointhnal hyperplasia in patients with in-stent restenosis: Late angiographic and intravascular ultrasound results. Ibid. (5, suppl. A, 37A): 823-831.